<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03312842</url>
  </required_header>
  <id_info>
    <org_study_id>CS1001-101</org_study_id>
    <nct_id>NCT03312842</nct_id>
  </id_info>
  <brief_title>A Phase Ia/Ib Study of CS1001 in Advanced Solid Tumors</brief_title>
  <official_title>A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-L1 Monoclonal Antibody CS1001 in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CStone Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CStone Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase Ia/Ib, open-label, multiple-dose, dose-escalation and expansion study to
      evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1001 in
      subjects with advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2017</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From first dose to 30 days after last dose of CS1001, up to 2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>CS1001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS1001</intervention_name>
    <description>In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.
In the dose expansion part, patients will be assigned to different groups based on their tumor type.</description>
    <arm_group_label>CS1001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. With advanced-stage or metastatic tumor (unresectable) and experienced progression
             since last anti-tumor treatment; standard therapy is not available or rejected.

          2. ECOG performance status of 0 or 1.

          3. Subjects must have at least one measurable lesion.

          4. Patients with life expectancy ≥ 3 months.

          5. Subject must have adequate organ function.

          6. Fertile men and women of childbearing potential must agree to use an effective method
             of birth control from providing signed consent and for 180 days after last study drug
             administration.

        Exclusion Criteria:

          1. Known brain metastasis or other CNS metastasis that is either symptomatic or
             untreated.

          2. Subjects with active autoimmune diseases or history of autoimmune diseases should be
             excluded.

          3. Patients who have received immune checkpoint proteins/antibody/medicine (including
             PD-1, PD-L1, etc) for treatment.

          4. Known history of HIV infection.

          5. Hepatitis B surface antigen (HBsAg) and Hepatitis B core antibody (HBcAb) positive or
             Hepatitis C virus (HCV) antibody positive.

          6. Any unresolved CTCAE Grade ≥ 2 toxicities from prior anti-cancer therapy with the
             exception of vitiligo, alopecia.

          7. Patients who have serious hypersensitive reaction to monoclonal antibodies, and have
             history of uncontrolled allergic asthma.

          8. Known history of alcoholism or drugs abuse.

        For more information regarding trial participation, please contact at
        cstonera@cstonepharma.com
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Yang, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CStone Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason Yang, MD, PhD</last_name>
    <phone>+86 21 61097678</phone>
    <email>cstonera@cstonepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2017</study_first_submitted>
  <study_first_submitted_qc>October 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

